SIM-0500

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameSIM-0500
Drug Alias NameSIM-0500SIM0500
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT lymphocytes stimulantsAnti-GPRC5DAnti-BCMA +[4] 
TargetsG-protein coupled receptor family C group 5member DB-cell maturation proteinT cell surface glycoprotein CD3
Therapy Area/IndicationsBone Marrow NeoplasmsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSimcere Pharmaceutical Group Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHainan Xiansheng Re Ming Pharmaceutical Co LtdShanghai Xiansheng Zaiming Pharmaceutical Biotechnology Co LtdAbbvie Inc +[5] 
Inactive CompaniesN/A
Active IndicationsBone Marrow NeoplasmsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A